Tempest Therapeutics (TPST) Net Income (2012 - 2026)
Tempest Therapeutics (TPST) posted Net Income of -$4.1 million for Q4 2025, up 71.67% sequentially from -$14.4 million in Q3 2025, and up 71.2% YoY from -$2.4 million in Q4 2024.
Tempest Therapeutics (TPST) Net Income (2012 - 2026) Analysis & Trends
Tempest Therapeutics has reported Net Income for 14 years, with the latest figure at -$4.1 million in Q4 2025.
- Quarterly Net Income rose 71.2% year-over-year to -$4.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$40.1 million (up 7.39% YoY) and the FY2025 annual result came in at -$28.8 million, up 86.85% from the prior year.
- Net Income rose to -$4.1 million in Q4 2025 per TPST's latest filing, from -$14.4 million in the prior quarter.
- Over five years, Net Income peaked at -$1.7 million in Q4 2023 and troughed at -$14.4 million in Q3 2025.
- A 5-year average of -$8.5 million and a median of -$8.7 million in 2021 frame the typical range for Net Income.
- The sharpest annual moves came in 2021 and 2024: Net Income soared 88.94% in 2021, then sank 733.14% in 2024.
- Over 5 years, Net Income stood at -$3.8 million in 2021, then sank by 147.19% to -$9.4 million in 2022, then jumped by 81.86% to -$1.7 million in 2023, then sank by 733.14% to -$14.2 million in 2024, then jumped by 71.2% to -$4.1 million in 2025.
- According to Business Quant data, Net Income over the past three periods registered -$4.1 million, -$14.4 million, and -$10.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 81.49 Mn |
| 10 | Tempest Therapeutics | 4.46 Mn | 3.66 Mn | - | -5.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.25 Mn |
| Dec 31, 2025 | -4.08 Mn |
| Sep 30, 2025 | -14.39 Mn |
| Jun 30, 2025 | -10.56 Mn |
| Mar 31, 2025 | -11.10 Mn |
| Dec 31, 2024 | -14.16 Mn |
| Sep 30, 2024 | -10.88 Mn |
| Jun 30, 2024 | -9.95 Mn |
| Mar 31, 2024 | -8.34 Mn |
| Dec 31, 2023 | -1.70 Mn |
| Sep 30, 2023 | -6.97 Mn |
| Jun 30, 2023 | -7.83 Mn |
| Mar 31, 2023 | -7.93 Mn |
| Dec 31, 2022 | -9.37 Mn |
| Sep 30, 2022 | -9.05 Mn |
| Jun 30, 2022 | -9.23 Mn |
| Mar 31, 2022 | -8.85 Mn |
| Dec 31, 2021 | -3.79 Mn |
| Sep 30, 2021 | -8.49 Mn |
| Jun 30, 2021 | -7.06 Mn |